WIPF2 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:147179, HGNC:30923, MIM:609692, NM_133264, NP_573571, WAS/WASL interacting protein family member 2, WICH, WIPF2, WIRE, XM_005257083, XM_005257084, XM_011524412, XM_011524413, XP_005257140, XP_005257141, XP_011522714, XP_011522715

Id:ENSG00000171475

Entrez:147179

Ensembl:ENSG00000171475

Description:WAS/WASL interacting protein family member 2

This gene encodes a WASP interacting protein (WIP)-related protein. It has been shown that this protein has a role in the WASP-mediated organization of the actin cytoskeleton and that this protein is a potential link between the activated platelet-derived growth factor receptor and the actin polymerization machinery. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View WIPF2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with WIPF2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using WIPF2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for WIPF2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with WIPF2.

Results found

Linked to

	Label	Description
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 12 V 6 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 12 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 enzalutamide prostate gland 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE208350 H-7 Huh-7 JHH-7 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 1 GLUTATHIONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 12 V 6 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 12 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE125014 enzalutamide prostate gland 1 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE208350 H-7 Huh-7 JHH-7 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE226285 3 V 1 GLUTATHIONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.